East Windsor, N.J. – Aurobindo Pharma Limited has received final approval from U.S. Food and Drug Administration for its Abbreviated New Drug Application Mometasone Furoate Monohydrate Nasal Spray, 50 mcg/spray. Aurobindo Pharma’s Mometasone Furoate Monohydrate Nasal Spray, are an AB-rated generic equivalent to the reference listed drug (RLD), Nasonex Nasal Spray manufactured by Organon LLC.

Mometasone Furoate Monohydrate Nasal Spray are indicated for:

• The treatment of the nasal symptoms of seasonal allergic and perennial allergic rhinitis, in adults and pediatric patients 2 years of age and older
• The relief of nasal congestion associated with seasonal allergic rhinitis, in adults and pediatric patients 2 years of age and older
• The prophylaxis of the nasal symptoms of seasonal allergic rhinitis in adult and adolescent patients 12 years and older
• The treatment of nasal polyps in patients 18 years of age and older.